Johnson & Johnson agreed to acquire Firefly Bio, Inc. for $1 billion in cash, the company said Monday, expanding its cancer drug pipeline with a platform designed to treat tumors that have resisted conventional therapies.
At the heart of the deal is Firefly’s Firelink platform, which is designed to slip protein-degrading drugs inside cancer cells by hitching them to antibodies — a strategy intended to spare healthy tissue from the collateral damage typical of existing treatments, Reuters reported. The platform targets tumors driven by a mutation in a gene known as KRAS, the company said.
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, executive vice president of innovative medicine, research and development at Johnson & Johnson, in a statement. “We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.”
Pending regulatory approvals and other standard closing conditions, J&J expects the deal to be finalized before the end of 2026.
The acquisition adds to Johnson & Johnson’s oncology business at a moment of broad momentum across its Innovative Medicine segment. The company reported first-quarter revenue of $24.1 billion, up about 10% from a year earlier, and raised its full-year 2026 sales outlook to a range of $100.3 billion to $101.3 billion. Growth in the quarter was driven in part by oncology therapies including Darzalex, which brought in $4.0 billion. J&J also committed more than $1 billion during the quarter to build a cell therapy manufacturing facility in Pennsylvania.
